Clinical Trial Update: Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke [Phase 2]

View source ↗

Summary

This entry reports on a Phase 2 trial evaluating CBG000592 (riboflavin/Vitamin B2) in patients with acute ischemic stroke. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• CBG000592 (Riboflavin/Vitamin B2) (riboflavin (vitamin B2))

Snippet

Sponsor: Castillo, José, M.D. | Conditions: Ischemic Stroke | Phase 2 | Status: COMPLETED